4/19
07:00 pm
mnpr
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
Medium
Report
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
3/30
08:02 am
mnpr
Monopar Therapeutics (MNPR) had its "buy" rating reaffirmed by Chardan Capital. They now have a $100.00 price target on the stock.
Medium
Report
Monopar Therapeutics (MNPR) had its "buy" rating reaffirmed by Chardan Capital. They now have a $100.00 price target on the stock.
3/27
04:51 pm
mnpr
Monopar Therapeutics GAAP EPS of -$0.61 misses by $0.16 [Seeking Alpha]
Low
Report
Monopar Therapeutics GAAP EPS of -$0.61 misses by $0.16 [Seeking Alpha]
3/27
01:00 pm
mnpr
Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
Low
Report
Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
3/2
08:00 am
mnpr
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer
Medium
Report
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer
2/23
08:04 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $104.00 price target on the stock.
Low
Report
Monopar Therapeutics (NASDAQ:MNPR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $104.00 price target on the stock.
2/2
08:05 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $104.00 price target on the stock.
Medium
Report
Monopar Therapeutics (NASDAQ:MNPR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $104.00 price target on the stock.
1/29
08:27 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $100.00 price target on the stock.
Medium
Report
Monopar Therapeutics (NASDAQ:MNPR) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $100.00 price target on the stock.
1/21
10:12 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Low
Report
Monopar Therapeutics (NASDAQ:MNPR) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.